145 related articles for article (PubMed ID: 17657254)
1. Gemtuzumab therapy for isolated extramedullary AML relapse following allogeneic stem-cell transplant.
Owonikoko T; Agha M; Balassanian R; Smith R; Raptis A
Nat Clin Pract Oncol; 2007 Aug; 4(8):491-5. PubMed ID: 17657254
[TBL] [Abstract][Full Text] [Related]
2. Gemtuzumab ozogamicin therapy for isolated extramedullary AML relapse after allogeneic hematopoietic stem-cell transplantation.
Ando T; Mitani N; Matsunaga K; Nakazora T; Gondo T; Yujiri T; Tanizawa Y
Tohoku J Exp Med; 2010 Feb; 220(2):121-6. PubMed ID: 20139663
[TBL] [Abstract][Full Text] [Related]
3. Preliminary results of the safety of immunotherapy with gemtuzumab ozogamicin following reduced intensity allogeneic stem cell transplant in children with CD33+ acute myeloid leukemia.
Roman E; Cooney E; Harrison L; Militano O; Wolownik K; Hawks R; Foley S; Satwani P; Unal E; Bhatia M; Bradley B; Del Toro G; George D; Garvin J; van de Ven C; Cairo MS
Clin Cancer Res; 2005 Oct; 11(19 Pt 2):7164s-7170s. PubMed ID: 16203817
[TBL] [Abstract][Full Text] [Related]
4. Treatment of relapsed acute myeloid leukemia with MLL/AF6 fusion after allogeneic hematopoietic stem cell transplantation with gemtuzumab ozogamicin with a long interval followed by donor lymphocyte infusion.
Tamai H; Shioi Y; Yamaguchi H; Okabe M; Wakita S; Mizuki T; Nakayama K; Inokuchi K; Tajika K; Dan K
Leukemia; 2008 Jun; 22(6):1273-4. PubMed ID: 17989711
[No Abstract] [Full Text] [Related]
5. Treatment of relapsed or refractory acute promyelocytic leukemia.
Tallman MS
Best Pract Res Clin Haematol; 2007 Mar; 20(1):57-65. PubMed ID: 17336255
[TBL] [Abstract][Full Text] [Related]
6. Isolated extramedullary relapse of acute myelogenous leukemia as a uterine granulocytic sarcoma in an allogeneic hematopoietic stem cell transplantation recipient.
Maeng H; Cheong JW; Lee ST; Yang WI; Hahn JS; Ko YW; Min YH
Yonsei Med J; 2004 Apr; 45(2):330-3. PubMed ID: 15119007
[TBL] [Abstract][Full Text] [Related]
7. Gemtuzumab ozogamicin (Mylotarg) in children with refractory or relapsed acute myeloid leukemia.
Reinhardt D; Diekamp S; Fleischhack G; Corbacioglu C; Jürgens H; Dworzak M; Kaspers G; Creutzig U; Zwaan CM
Onkologie; 2004 Jun; 27(3):269-72. PubMed ID: 15249716
[TBL] [Abstract][Full Text] [Related]
8. Granulocytic sarcoma of the heart: extramedullary relapse of acute myeloblastic leukemia after allogeneic stem cell transplantation successfully treated by chemotherapy alone.
Kara IO; Sahin B; Paydas S; Kara B
Leuk Lymphoma; 2005 Jul; 46(7):1081-4. PubMed ID: 16019562
[TBL] [Abstract][Full Text] [Related]
9. Comparative efficacy and safety of gemtuzumab ozogamicin monotherapy and high-dose cytarabine combination therapy in patients with acute myeloid leukemia in first relapse.
Leopold LH; Berger MS; Cheng SC; Cortes-Franco JE; Giles FJ; Estey EH
Clin Adv Hematol Oncol; 2003 Apr; 1(4):220-5. PubMed ID: 16224410
[TBL] [Abstract][Full Text] [Related]
10. Multiple extramedullary relapses without bone marrow involvement after second allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia.
Yoo SW; Chung EJ; Kim SY; Ko JH; Baek HS; Lee HJ; Oh SH; Jeon SC; Lee WS; Park CK; Lee CH
Pediatr Transplant; 2012 Jun; 16(4):E125-9. PubMed ID: 21923886
[TBL] [Abstract][Full Text] [Related]
11. A new combination of carboplatin, high-dose cytarabine and cross-over mitoxantrone or idarubicin for refractory and relapsed acute myeloid leukemia.
Bassan R; Lerede T; Buelli M; Borleri G; Bellavita P; Rambaldi A; Barbui T
Haematologica; 1998 May; 83(5):422-7. PubMed ID: 9658726
[TBL] [Abstract][Full Text] [Related]
12. Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia.
Bross PF; Beitz J; Chen G; Chen XH; Duffy E; Kieffer L; Roy S; Sridhara R; Rahman A; Williams G; Pazdur R
Clin Cancer Res; 2001 Jun; 7(6):1490-6. PubMed ID: 11410481
[TBL] [Abstract][Full Text] [Related]
13. Myeloid sarcoma of the vulva post-bone marrow transplant presenting as isolated extramedullary relapse in a patient with acute myeloid leukemia.
Nazer A; Al-Badawi I; Chebbo W; Chaudhri N; El-Gohary G
Hematol Oncol Stem Cell Ther; 2012; 5(2):118-21. PubMed ID: 22828376
[TBL] [Abstract][Full Text] [Related]
14. Fractionated gemtuzumab ozogamicin in association with high dose chemotherapy: a bridge to allogeneic stem cell transplantation in refractory and relapsed acute myeloid leukemia.
Debureaux PE; Labopin M; Mamez AC; Lapusan S; Isnard F; Adaeva R; Bonnin A; Hirsch P; Delhommeau F; Battipaglia G; Duléry R; Malard F; Vekhoff A; Mohty M; Legrand O; Brissot E
Bone Marrow Transplant; 2020 Feb; 55(2):452-460. PubMed ID: 31554931
[TBL] [Abstract][Full Text] [Related]
15. Gemtuzumab ozogamicin-induced long-term remission in a woman with acute myelomonocytic leukemia and bone marrow relapse following allogeneic transplantation.
Sumi M; Ichikawa N; Nasu K; Shimizu I; Ueki T; Ueno M; Kobayashi H
Int J Hematol; 2009 Dec; 90(5):643-647. PubMed ID: 19904520
[TBL] [Abstract][Full Text] [Related]
16. Treatment of refractory and relapsed acute myelogenous leukemia.
Stanisic S; Kalaycio M
Expert Rev Anticancer Ther; 2002 Jun; 2(3):287-95. PubMed ID: 12113052
[TBL] [Abstract][Full Text] [Related]
17. Low dose gemtuzumab ozogamicin for relapsed acute myeloid leukaemia in elderly.
Piccaluga PP; Martinelli G; Rondoni M; Malagola M; Ronconi S; Visani G; Baccarani M
Haematologica; 2003 Dec; 88(12):ECR37. PubMed ID: 14688010
[No Abstract] [Full Text] [Related]
18. Isolated cavernous sinus extramedullary relapse of chronic myelogenous leukemia following allogeneic stem cell transplant.
Martel L; Reddy K; Greco M; Tuscano M; Richman M; Wun T
Ann Hematol; 2002 Feb; 81(2):108-10. PubMed ID: 11907793
[TBL] [Abstract][Full Text] [Related]
19. Sequential administration of gemtuzumab ozogamicin and conventional chemotherapy as first line therapy in elderly patients with acute myeloid leukemia: a phase II study (AML-15) of the EORTC and GIMEMA leukemia groups.
Amadori S; Suciu S; Willemze R; Mandelli F; Selleslag D; Stauder R; Ho A; Denzlinger C; Leone G; Fabris P; Muus P; Vignetti M; Hagemeijer A; Beeldens F; Anak O; De Witte T; ;
Haematologica; 2004 Aug; 89(8):950-6. PubMed ID: 15339678
[TBL] [Abstract][Full Text] [Related]
20. Outcomes of patients with AML and MDS who relapse or progress after reduced intensity allogeneic hematopoietic cell transplantation.
Pollyea DA; Artz AS; Stock W; Daugherty C; Godley L; Odenike OM; Rich E; Smith SM; Zimmerman T; Zhang Y; Huo D; Larson R; van Besien K
Bone Marrow Transplant; 2007 Dec; 40(11):1027-32. PubMed ID: 17846595
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
